December, 2017: In the December issue of Ophthalmology Management, Citrus Therapeutics is highlighted as a recent finalist in The Winning Pitch Challenge.
The article notes that a “single, under-development product, CTX1, is a novel agent designed for the treatment of both the dry and wet AMD. Its mechanism of action includes both antioxidant activity ideal for oxidative stress encountered in dry AMD and nonselective interference with nicotinic acetylcholine angiogenic pathways that may have utility in both dry and wet forms of AMD.”
Read the entire article here.
August 2017: Citrus Therapeutics were selected as finalists for the inaugural ASRS Winning Pitch Challenge. We presented rationale for our new early phase therapeutic, CTX1, a novel agent for the treatment of age-related macular degeneration. Although we did not win, we are grateful for the feedback and honored to be on stage with a diverse group of innovative retina specialists. The “Shark Tank” atmosphere with a fantastic panel of judges and investors was a lot of fun and we look forward to more in the future.
Ideas. Innovation. Insight.
About / Citrus Therapeutics is an ophthalmic company serving scientists, clinicians, and patients.
For scientists, Citrus focuses on the development of novel therapeutics and technologies and evaluation of novel drugs for the treatment of ocular disease.
For clinicians, Citrus is innovating the way clinical images are shared by developing cloud-based technology solutions. Citrus innovations bring accessibility and collaboration to the forefront of our technology, while preserving patient privacy.
For patients, Citrus seeks to develop an online community by offering a mobile application and website that enables patients with eyes disease to connect, share, and communicate with each other.